Monday, February 3, 2020 Daily Archives

Catalent to buy Orgenesis’ cell therapy CDMO biz for $315m

by

Last year Catalent entered the gene therapy space, now the CDMO will expand into cell therapies through the acquisition of Masthercell from Orgenesis. The deal includes a plant in Belgium and a site under construction in Texas. The deal sees contract development and manufacturing organization (CDMO) Catalent paying $315 million (€285 million) for Orgenesis’ third-party cell and gene therapy business Masthercell. Orgenesis will receive around $127 million of this with Masthercell’s backers Great Point Partners and SFPI-FPIM presumably receiving the…

February 3, 2020

Takeda divesting former-Shire $400m plant with 200 staff in Ireland

by

Takeda has identified a biomanufacturing facility in Dunboyne, Ireland as no longer required in a strategic review of its production network following the acquisition of Shire. In January 2019, Takeda completed its $62 billion (€56 billion) acquisition of Shire. As part of its integration, the firm said it intended to divest up to 25% of the combined business. Part of this strategy includes a biologics facility in Dunboyne, County Meath Ireland. “A strategic review of Takeda’s global biologics manufacturing network,…

February 3, 2020

Potential Oklahoma anti-vax bill danger to health and industry

by

Oklahoma has introduced a bill intended to ban the state from prescribing, administering, and making medicinal products and vaccines containing human DNA. Introduced on January 15, Senate Bill 1514 is proposing prohibiting vaccine use and supply in the state of Oklahoma. “No medicine, medical product, vaccine or other injection that contains human DNA shall be prescribed, administered, dispensed, used or offered in this state,†the bill states, placing a date of November 1, 2020 as the when it hopes to…

February 3, 2020